Pancreatic Cancer Research

ResearcherUniversity of Nebraska Medical CenterActive in the last 2 years

Namita Bhyravbhatla

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6164-8308; OpenAlex author ID A5004812157. Sources: OpenAlex.

Their work

Papers
8 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
42
Papers, trials and grants by year

2022: 3 papers · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 3 papers

Papers 8

  1. Unique N-glycoproteomics and phosphoproteomics of mucins predict clinical outcomes in pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.canlet.2026.218653↗
  2. Targeting Oncomucin-Driven Immunosuppression Improves the Efficacy of K-ras G12D Inhibition in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2026.04.041↗
  3. Unlocking the Power of CXCR2 Inhibition to Overcome Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.1096/fba.2025-00265↗
  4. Targeting cancer-associated fibroblast-driven LIF/LIFR axis improves the therapeutic efficacy of gemcitabine and nab-paclitaxel in pancreatic cancer. Co-author DOI 10.1038/s41698-025-01046-w↗
  5. MUC16 and TP53 family co-regulate tumor-stromal heterogeneity in pancreatic adenocarcinoma. Co-author DOI 10.3389/fonc.2023.1073820↗
  6. Cytokines chattering in pancreatic ductal adenocarcinoma tumor microenvironment. First author DOI 10.1016/j.semcancer.2022.03.021↗
  7. Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-022-02493-6↗
  8. MUC16 Promotes Liver Metastasis of Pancreatic Ductal Adenocarcinoma by Upregulating NRP2-Associated Cell Adhesion. Co-author DOI 10.1158/1541-7786.mcr-21-0888↗

Closest collaborators

The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Surinder K. Batra · 8 shared papers, 2022–2026 · strength 1.78
  2. Zahraa Wajih Alsafwani · 4 shared papers, 2023–2026 · strength 1.05
  3. Sushil Kumar K · 4 shared papers, 2022–2026 · strength 0.90
  4. Maneesh Jain · 4 shared papers, 2022–2025 · strength 0.62
  5. Moorthy Palanimuthu Ponnusamy · 4 shared papers, 2022–2025 · strength 0.62
  6. Sushil Kumar · 2 shared papers, 2026 · strength 0.54
  7. Rick Bhatia · 2 shared papers, 2025–2026 · strength 0.51
  8. Pranita Atri · 3 shared papers, 2022–2026 · strength 0.48
  9. Saravanakumar Marimuthu · 3 shared papers, 2022–2026 · strength 0.48
  10. Mokenge Peter Malafa · 2 shared papers, 2025–2026 · strength 0.45
  11. Shailendra Kumar Gautam · 3 shared papers, 2022–2025 · strength 0.45
  12. Imayavaramban Lakshmanan · 3 shared papers, 2022–2023 · strength 0.41
  13. Rama Krishna Nimmakayala · 3 shared papers, 2022–2023 · strength 0.41
  14. Xiaoqi Li Li · 2 shared papers, 2022–2025 · strength 0.40
  15. Parthasarathy Seshacharyulu · 2 shared papers, 2022–2025 · strength 0.32
  16. Caitlin Molczyk · 1 shared paper, 2026 · strength 0.30
  17. Sugandha Saxena · 1 shared paper, 2026 · strength 0.30
  18. Reegan Sturgeon · 1 shared paper, 2026 · strength 0.30
  19. Rakesh K. Singh · 1 shared paper, 2026 · strength 0.30
  20. Ramakanth Chirravuri‐Venkata · 2 shared papers, 2022–2023 · strength 0.28
  21. Krystal Villalobos-Ayala · 1 shared paper, 2026 · strength 0.24
  22. Palanisamy Nallasamy · 1 shared paper, 2026 · strength 0.24
  23. Jesse L. Cox · 1 shared paper, 2026 · strength 0.24
  24. Imran Khan · 1 shared paper, 2026 · strength 0.24
  25. Margaret A. Park · 1 shared paper, 2026 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.